Answers are grounded in this paper and cite their sources.
Background Cholesterol metabolism plays a pivotal role in cancer progression and treatment resistance. This study investigates the effects of exogenous cholesterol on cell viability and migration, both as a monotherapy and in combination with carboplatin, in ovarian cancer cell lines representing disease progression: PEO1, PEO4, and PEO6. Methods PEO1, PEO4, and PEO6 cells were treated with 1 µg/mL or 5 µg/mL cholesterol, with or without carboplatin (100 µM or 200 µM). Cell viability was assessed with a luminescent adenosine triphosphate assay (CellTiter-Glo), and migration was measured using wound healing assays. Treatment groups were compared within each cell line by one-way analysis of variance. Results Cholesterol alone significantly enhanced viability in all three cell lines, with the most robust and consistent effects observed in PEO1 cells. Co-treatment with cholesterol and carboplatin further increased viability compared to carboplatin alone, suggesting a cholesterol-mediated protective effect, most prominent in PEO1 and PEO4. Cholesterol also promoted cell migration in all three lines, with a significant dose effect only in PEO4, with PEO1 showing the strongest enhancement. While carboplatin inhibited migration, cholesterol partially reversed this effect, particularly in PEO1, PEO4 and PEO6 lines who demonstrated modest recovery. Conclusions Exogenous cholesterol promotes ovarian cancer cell viability and migration and mitigates carboplatin-induced suppression in a cell line–specific manner. The most pronounced effects were seen in PEO1, suggesting a potential link between cholesterol dysregulation and chemoresistance. These findings underscore the importance of considering lipid metabolism in therapeutic strategies for ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Qusairy et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: